Kodiak Sciences Inc Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for KOD, updated each market day.
KOD AI Sentiment
AI predicts Kodiak Sciences Inc Common Stock stock is likely to increase over the next 10 market days.
Prediction date: Sept. 22, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About Kodiak Sciences Inc Common Stock
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
Sector
Exchange
Market Cap
$2,064,604,662
Cap Tier
Employees
124
Headquarters
PALO ALTO, CA
Listed Since
Oct. 4, 2018
Website
KOD Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
KOD Volatility
Kodiak Sciences Inc Common Stock has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
